07:13 AM EST, 11/05/2025 (MT Newswires) -- Recursion Pharmaceuticals ( RXRX ) reported a Q3 loss Wednesday of $0.36 per diluted share, widening from a loss of $0.34 a year earlier.

Analysts polled by FactSet expected a loss of $0.38.

Revenue for the quarter ended Sept. 30 was $5.2 million, down from $26.1 million a year earlier.

Analysts surveyed by FactSet expected $17 million.

As of Oct. 9, Recursion Pharmaceuticals ( RXRX ) said it had $785 million in cash and cash equivalents, which it expects to provide it with a cash runway through the end of 2027.

Shares of the company were down 2.6% in recent Wednesday premarket activity.